Skip to main content
. 2021 Aug 18;21:568. doi: 10.1186/s12884-021-04017-8

Table 2.

Comparison of patients’ intraoperative and postoperative conditions treated by the three different strategies (n = 51)

items mifepristone + misoprostol mifepristone + Rivanol hysterotomy p
(n = 16) (n = 14) (n = 21)
Bleeding volume in 24 h of surgery(mL) 672.50 ± 673.42 528.57 ± 610.08 752.38 ± 1310.58 0.626b
Rescue rate (n,%) 11(68.8) 8(57.1) 8(38.1) 0.168c
Blood transfusion rate (n,%) 6(37.5) 2(14.3) 4(19.0) 0.268c
Hysterectomy rate (n, %) 0(0) 1(7.1) 3(14.3) 0.286c
Main operative success rate (n,%) 5(31.3) 5(35.7) 18(85.7) 0.001c
Hospital stay(d) 10.69 ± 4.38 12.79 ± 8.40 11.57 ± 3.11 0.795b
Blood β-hCG decline of 3rd days after treatment (%) 92.79 ± 8.81 91.96 ± 8.33 91.85 ± 6.55 0.354b
Time of β-hCG recovery (d) 40.06 ± 1.56* 37.21 ± 2.39 32.95 ± 1.79* 0.028a
Time of menstrual recovery (d) 54.13 ± 2.67 55.50 ± 5.05 48.24 ± 4.03 0.195b
Residual placenta 0.739c
Expecting treatment 3(18.8) 4(28.6) 3(15.0)
Medical treatment 10(62.5) 6(42.9) 10(50.0)
Surgical treatment 3(18.8) 4(28.6) 7(35.0)

Data are presented as mean ± SD and count (%)

aOne-way analysis of variance, brank sum test of multiple independent samples, c χ2 test. *Bonferroni adjustment p < 0.017